Key result
Recombinant GDF11 dose-dependently decreased cardiac hypertrophy and improved pump function, but the highest dose (5.0 mg/kg) caused severe cachexia and death in mice.
Why the study?
Does recombinant GDF11 reduce pressure overload-induced cardiac hypertrophy in a mouse model?
Does recombinant GDF11 reduce pressure overload-induced cardiac hypertrophy in a mouse model?
While GDF11 reduces pathological cardiac hypertrophy and improves pump function in pressure overload, high doses cause severe cachexia and premature death, highlighting a potentially dangerous toxicity profile.
No takes yet. Share an insight, caveat, or question.
Animal data on GDF11 dose effects leave open any role in human hypertrophy or HF therapy.
Harper et al. (2018) studied Pressure overload-induced cardiac hypertrophy. rGDF11 (recombinant GDF11) was evaluated on Cardiac hypertrophy, cardiac pump function, and body weight/survival. Recombinant GDF11 dose-dependently decreased cardiac hypertrophy and improved pump function, but the highest dose (5.0 mg/kg) caused severe cachexia and death in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: